On Monday, Arrowhead Research Corp (NASDAQ:ARWR)’s shares declined -13.22% to $6.30.
Arrowhead Research Corporation (ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, recently declared that it has nominated ARC-HIF2 as its first therapeutic candidate delivered using a new Dynamic Polyconjugate™ (DPC™) designed to target tissues outside of the liver. Arrowhead believes that ARC-HIF2, which uses RNA interference to silence transcription factor hypoxia-inducible factor 2α (HIF-2α), is a promising new candidate for the treatment of clear cell renal cell carcinoma (ccRCC). The company will present preclinical data at the European Cancer Congress 2015 (ECC2015) in Vienna on September 27 in a session starting at 16:45 CEST. In a poster titled “HIF-2α targeting with a novel RNAi delivery platform as therapy for renal cell carcinoma,” (abstract #353), Arrowhead scientists will show data suggesting that HIF-2α inhibition through RNA interference may significantly impact late stage ccRCC progression. The company is in the process of manufacturing scale up to allow for initiation of IND-enabling studies. Timing for anticipated regulatory submission will be declared in the future.
Using ARC-HIF2 in a preclinical ccRCC tumor model, mice treated with weekly injections led to greater than 80% knockdown of HIF-2α mRNA in tumors. Furthermore, tumors from treated mice exhibited statistically noteworthy reductions in size and weight, extensive tumor cell death, reduction in the tumor-expressed VEGF-A biomarker, and destruction of the blood vessels feeding the tumors.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
Ally Financial Inc (NYSE:ALLY)’s shares dropped -3.51% to $20.05.
In honor of local students going back to school this week, Ally Financial declared that it will be donating 3,000 new library books to schools in the Detroit Public School district. Elementary and middle school libraries throughout the district will receive 50 new books that focus on various financial literacy skills and concepts, with selections for pre-kindergarten through eighth grade reading levels.
Ally’s city-wide book donation kicked off at Spain Elementary-Middle School in Detroit this morning, where Ally volunteers hand-delivered the new books to the school. Volunteers also surprised all 650 students at Spain with additional school supplies, counting pens, pencils, notebooks, scissors, extra paper and other necessities for their school year.
Ally Financial Inc. provides financial products and services primarily to automotive dealers and their customers in the United States. It offers dealer financial services, counting a range of financial services and insurance products to automotive dealers and retail customers.
At the end of Monday’s trade, Orexigen Therapeutics, Inc. (NASDAQ:OREX)‘s shares dipped -1.92% to $2.04.
Orexigen Therapeutics, Inc. (OREX) declared receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals, Orexigen’s United States partner for Contrave® (naltrexone HCl and bupropion HCl extended release). Two additional potential $15 million anniversary milestone payments are predictable from Takeda in the fourth quarter of each of 2016 and 2017.
Orexigen also declared receipt of the $7 million upfront payment from Kwang Dong Pharmaceutical Company Ltd., based in Seoul, Korea. In August 2015, Orexigen and Kwang Dong executed a Korean distributorship agreement for Contrave. Kwang Dong anticipates to start marketing Contrave in the second half of 2016, if regulatory approval is obtained.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity.
Servicemaster Global Holdings Inc (NYSE:SERV), ended its Monday’s trading session with -3.22% loss, and closed at $32.48.
ServiceMaster Global Holdings, Inc. (SERV), a leading provider of essential residential and commercial services, declared several executive moves designed to assist the company pursue new growth opportunities and advance the use of digital and mobile technologies to improve service to the 5 million customers it serves each year.
Mark Barry has been promoted to chief marketing and strategy officer. Barry joined ServiceMaster in 2012 as president of its American Home Shield home warranty business and has been serving as group president leading both AHS and the company’s Franchise Services Group. In his new role, Barry will oversee company strategy, counting competitive intelligence, insights and analytics, in addition to all marketing, pricing and business development.
ServiceMaster Global Holdings, Inc. provides residential and commercial services in the United States. It operates in three segments: Terminix, American Home Shield, and the Franchise Services Group.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
